Business Context and Reporting Period
Company: AtriCure, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: AtriCure is a medical device company specializing in cardiac surgical ablation systems for the treatment of atrial fibrillation (AF). Its primary product line is the Isolator Synergy bipolar ablation clamp system. The company also offers cryoablation devices and the AtriClip system for excluding the left atrial appendage. While products are used off-label for AF treatment, none have received FDA approval for this specific indication as of the filing date. International sales accounted for 19% of total revenues in 2009.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenues | $54.5 million | $55.3 million |
| Gross Profit | $41.8 million | $42.0 million |
| Gross Margin | 76.6% | 76.1% |
| Net Loss | $(16.5) million | $(10.2) million |
| Operating Expenses | $57.3 million | $53.0 million |
| Cash and Short-Term Investments | $15.7 million | $11.4 million |
| Working Capital | $19.5 million | $18.0 million |
| Total Debt (Current + Long-Term) | $4.9 million | $6.0 million |
| Accumulated Deficit | $(94.0) million | $(77.5) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 1.3% to $54.5 million. Domestic revenues fell 6.0% due to a decrease in minimally invasive product sales, partially offset by a 24.9% increase in international revenues.
- Increased Net Loss: Net loss widened to $16.5 million from $10.2 million in 2008. This was driven primarily by two significant non-cash charges: a $6.8 million goodwill impairment and a $4.0 million settlement reserve related to a Department of Justice (DOJ) investigation.
- Operating Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased by $7.3 million (17.2%) due to reduced headcount and travel expenses following a sales force reduction in late 2008.
- Goodwill Impairment: The company recorded a full impairment of $6.8 million in goodwill during the first quarter of 2009 due to a reduction in market capitalization.
- DOJ Settlement: A tentative settlement was reached regarding a DOJ investigation into marketing practices and billing codes, resulting in a $4.0 million charge (net present value) in 2009. The settlement was finalized in February 2010 for approximately $4.35 million including interest.
Guidance, Outlook, Risks, and Contingencies
- Regulatory Outlook: The company anticipates submitting a Premarket Approval (PMA) application to the FDA in the first half of 2010 for the Isolator system to treat permanent AF. The AtriClip system received CE Mark approval in Europe and launched in Q4 2009; FDA clearance for the U.S. is anticipated in the second half of 2010.
- Liquidity: Management believes current cash, cash equivalents, and short-term investments ($15.7 million) combined with access to a $10.0 million credit facility (with $6.5 million borrowed under a term loan) are sufficient to meet capital requirements for at least the next 12 months.
- Key Risks:
- Off-Label Promotion: The company faces significant regulatory risk as its products are used off-label for AF treatment. The DOJ investigation and subsequent Corporate Integrity Agreement highlight the scrutiny on marketing practices.
- Profitability: The company has a history of net losses and an accumulated deficit of $94.0 million. There is no assurance it will achieve profitability.
- Reimbursement: Changes in Medicare Severity Diagnosis Related Groupings (MS-DRGs) proposed for October 2010 could reduce reimbursement levels for sole-therapy minimally invasive AF treatment.
- Legal Proceedings: Two securities class action lawsuits are pending. A liability of $2.0 million was recorded for one case, while the liability for the second case is currently unestimable.
Investor Verification Checklist
- DOJ Settlement Terms: Verify the final payment schedule and ongoing compliance requirements under the five-year Corporate Integrity Agreement with the Office of Inspector General (OIG).
- Goodwill Impairment: Confirm the valuation methodology used for the $6.8 million impairment and assess the impact on future asset valuations.
- Class Action Litigation: Monitor the status of the two pending securities class action lawsuits, particularly the one where liability is currently unestimable.
- FDA PMA Submission: Track the timeline for the submission and review of the PMA application for the Isolator system, as FDA approval is critical for on-label marketing.
- Reimbursement Policy Changes: Evaluate the potential financial impact of the proposed CMS changes to MS-DRGs effective October 1, 2010.
- Debt Covenants: Review the financial covenants of the Silicon Valley Bank credit facility, noting recent waivers and amendments regarding compliance violations.